Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose

- 3
- 4 Francis Mwimanzi¹, Hope R. Lapointe², Peter K. Cheung^{1,2}, Yurou Sang¹, Fatima Yaseen¹, Gisele
- 5 Umviligihozo¹, Rebecca Kalikawe¹, Sneha Datwani¹, F. Harrison Omondi^{1,2}, Laura Burns³, Landon
- 6 Young³, Victor Leung^{4,5}, Olga Agafitei¹, Siobhan Ennis¹, Winnie Dong², Simran Basra¹, Li Yi Lim¹,
- 7 Kurtis Ng¹, Ralph Pantophlet¹, Chanson J. Brumme^{2,4}, Julio S.G. Montaner^{2,4}, Natalie Prystajecky^{5,6},
- 8 Christopher F. Lowe^{3,5}, Mari L. DeMarco^{3,5}, Daniel T. Holmes^{3,5}, Janet Simons^{3,5}, Masahiro Niikura¹,
- 9 Marc G. Romney^{3,5,*}, Zabrina L. Brumme^{1,2,*}, Mark A. Brockman^{1,2,*}
- 10
- 11 1. Faculty of Health Sciences, Simon Fraser University, Canada;
- 12 2. British Columbia Centre for Excellence in HIV/AIDS, Canada;
- 13 3. Division of Medical Microbiology and Virology, St. Paul's Hospital, Canada;
- 14 4. Department of Medicine, University of British Columbia, Canada;
- 15 5. Department of Pathology and Laboratory Medicine, University of British Columbia, Canada
- 16 6. British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, Canada
- 17 *MAB, MGR and ZLB contributed equally
- 18

19 Corresponding Author Contact Information:

- 20 Mark A. Brockman, Ph.D.
- 21 Professor, Faculty of Health Sciences, Simon Fraser University
- 22 8888 University Drive, Burnaby, BC, Canada, V5A 1S6
- 23 Tel: 778 782-3341; Fax: 778-782-5927; email: mark_brockman@sfu.ca

24 ABSTRACT

Background: Third COVID-19 vaccine doses are broadly recommended, but immunogenicity data
 remain limited, particularly in older adults.

27 Methods: We measured circulating antibodies against the SARS-CoV-2 spike protein receptor-binding

domain, ACE2 displacement, and virus neutralization against ancestral and Omicron (BA.1) strains

from pre-vaccine up to one month following the third dose, in 151 adults aged 24-98 years who

30 received COVID-19 mRNA vaccines.

31 **Results:** Following two vaccine doses, humoral immunity was weaker, less functional and less durable

32 in older adults, where a higher number of chronic health conditions was a key correlate of weaker

33 responses and poorer durability. Third doses boosted antibody binding and function to higher levels

34 than second-doses, and induced responses in older adults that were comparable in magnitude to those in

35 younger adults. Humoral responses against Omicron were universally weaker than against the ancestral

36 strain after both second and third doses; nevertheless, after three doses, anti-Omicron responses in older

37 adults reached equivalence to those in younger adults. After three vaccine doses, the number of chronic

38 health conditions, but not age per se, was the strongest consistent correlate of weaker humoral

39 responses.

40 Conclusion: Results underscore the immune benefits of third COVID-19 vaccine doses, particularly in
41 older adults.

42

Key words: COVID-19, mRNA vaccine, SARS-CoV-2, humoral immunity, older adults, binding
antibodies, ACE2 displacement, viral neutralization, Omicron

46 INTRODUCTION

47	Older adults are at increased risk of lethal COVID-19 following SARS-CoV-2 infection
48	(SARS-CoV-2) [1-3]. While two doses of a COVID-19 mRNA vaccine broadly protects against
49	hospitalization and death [4-6], weaker vaccine-induced immunity observed in the elderly and certain
50	other groups [7-12] has led to their prioritization to receive third doses [13-16]. Vaccine-induced
51	antibodies also decline over time, which can increase the risk of breakthrough infections [17-19],
52	particularly with the more transmissible and immune evasive Omicron variant (B.1.1.529) [20-22].
53	We and others have shown that older age is associated with weaker antibody responses to
54	COVID-19 mRNA vaccines, Comirnaty (Pfizer/BioNTech) and Spikevax (Moderna) [10-12]. We
55	previously characterized longitudinal humoral responses up to three months after the second vaccine
56	dose in a cohort of 151 adults 24 to 98 years of age that includes COVID-19 naïve and convalescent
57	individuals [12]. Here, we examine binding and neutralizing antibody responses up to six months
58	following the second vaccine dose, as well as one month following the third vaccine dose. We also
59	evaluate binding antibodies, ACE2 displacement, and virus neutralization against Omicron (BA.1) one
60	month following the second and third doses.

62 METHODS

63	Study design. We conducted a prospective longitudinal cohort study in British Columbia, Canada, to
64	examine SARS-CoV-2 specific humoral responses following vaccination with Comirnaty or Spikevax.
65	Our cohort of 151 individuals included 81 healthcare workers (HCW) and 56 older adults (including 18
66	residents of long-term care or assisted living facilities) who were COVID-19 naive at study entry, and
67	14 COVID-19 convalescent individuals with anti-SARS-CoV-2 N antibodies at study entry (including
68	8 HCW and 6 older adults) [12]. Serum and plasma were collected prior to vaccination; one month
69	after the first dose; one, three and six months after the second dose; and one month following the third
70	dose. Specimens were processed same-day and frozen until analysis.
71	
72	Ethics approval. Written informed consent was obtained from all participants or their authorized
73	decision makers. This study was approved by the University of British Columbia/Providence Health
74	Care and Simon Fraser University Research Ethics Boards.
75	
76	Data sources. Sociodemographic, health and vaccine information was collected by self-report and
77	confirmed through medical records where available. Chronic health conditions were defined as
78	hypertension, diabetes, asthma, obesity (body mass index \geq 30), chronic diseases of lung, liver, kidney,
79	heart or blood, cancer, and immunosuppression due to chronic conditions or medication, to generate a
80	score ranging from 0-11 per participant [12].
81	
82	Binding antibody assays. We measured total binding antibodies against SARS-CoV-2 nucleocapsid
83	(N) and spike (S) receptor binding domain (RBD) in serum using the Roche Elecsys Anti-SARS-CoV-

85	Diagnostics). Following SARS-CoV-2 infection, both assays should be positive, whereas post-
86	vaccination only the S assay should be positive, allowing identification of convalescent individuals.
87	Both tests are electro-chemiluminescence sandwich immunoassays, and report results in Arbitrary
88	Units (AU)/mL, calibrated against an external standard. For the S assay, the manufacturer indicates that
89	AU values can be considered equivalent to international binding antibody units (BAU) as defined by
90	the World Health Organization [23]. For the S assay, sera were tested undiluted, with samples above
91	the upper limit of quantification (ULOQ) re-tested at 1:100 dilution, allowing a measurement range of
92	0.4 - 25,000 U/mL. We also quantified plasma IgG binding antibodies against RBD using the V-plex
93	SARS-CoV-2 (IgG) Panel 22 ELISA kit (Meso Scale Diagnostics), which features the ancestral
94	(Wuhan) and Omicron RBD antigens, on a Meso QuickPlex SQ120 instrument. Plasma samples were
95	diluted 1:10000 as directed by the manufacturer, with results reported in Arbitrary Units (AU)/mL.
96	
97	ACE2 competition assay. We assessed the ability of plasma antibodies to block the RBD-ACE2
98	receptor interaction by competition ELISA (Panel 22 V-plex SARS-CoV-2 [ACE2]; Meso Scale
99	Diagnostics) on a Meso QuickPlex SQ120 instrument. Plasma was diluted 1:20 as directed by the
100	manufacturer and results reported as % ACE2 displacement.
101	
102	<i>Live virus neutralization.</i> Neutralizing activity in plasma was examined using a live SARS-CoV-2
103	infectivity assay in a Containment Level 3 facility. Assays were performed using isolate USA-
104	WA1/2020 (BEI Resources) and a local Omicron isolate (BA.1 strain; GISAID Accession #
105	EPI_ISL_9805779) on VeroE6-TMPRSS2 (JCRB-1819) target cells. Viral stock was adjusted to 50
106	$TCID_{50}/200 \ \mu l$ in Dulbecco's Modified Eagle Medium in the presence of serial 2-fold dilutions of
107	plasma (from 1/20 to 1/2560), incubated at 4°C for 1 hour and then added to target cells in 96-well

108	plates in triplicate. Cultures were maintained at 37°C with 5% CO ₂ and the appearance of viral
109	cytopathic effect (CPE) was recorded three days post-infection. Neutralizing activity is reported as the
110	highest reciprocal plasma dilution able to prevent CPE in all three replicate wells. Samples exhibiting
111	only partial or no neutralization at the lowest dilution of 1/20 were coded as having a reciprocal
112	dilution of "10", defined as below the limit of quantification (BLOQ) in this assay.
113	
114	Statistical analysis. Comparisons of binary variables were performed using Fisher's exact test.
115	Comparisons of continuous variables were performed using the Mann-Whitney U-test (for unpaired
116	data) or Wilcoxon test (for paired data). Multiple linear regression was used to investigate the
117	relationship between sociodemographic, health and vaccine-related variables and humoral outcomes.
118	Variables included age (per year increment), sex at birth (female as reference group), ethnicity (non-
119	white as reference), number of chronic health conditions (per number increment), mRNA vaccine
120	received (Comirnaty as reference), interval between doses (per day increment), sampling date
121	following the most recent dose (per day increment), and convalescent status (COVID-19 naive as
122	reference). Binding antibody half-lives in serum were calculated by fitting exponential decay curves to
123	antibody concentrations at one, three and six months after the second dose. All tests were two-tailed,
124	with p<0.05 considered statistically significant. Analyses were conducted using Microsoft Excel and
125	Prism v9.2.0 (GraphPad).

127 **RESULTS**

128 Participant characteristics

As described previously [12], the cohort is predominantly female (**Table 1**). HCW, older adults 129 and COVID-19 convalescent individuals at study entry were a median of 41, 79 and 48 years old, 130 131 respectively. Older adults were predominantly (77%) of white ethnicity (compared to 46% of HCW) 132 and had a higher burden of chronic health conditions (a median of 1, interquartile range [IQR] 0-2, range 0-5, vs. a median of 1, IQR 0-0, range 0-3 in HCW). All participants received two COVID-19 133 mRNA vaccine doses between December 2020-July 2021, where the dose interval was up to 112 days 134 135 as per national guidelines to delay second doses due to initially limited vaccine supply. A total of 141 (93%) and 138 (91%) of participants received Comirnaty as their first and second dose, respectively. At 136 137 the time of writing, 114 participants had received a third dose between October-December 2021, on average 7 months following their second dose. For participants whose third dose was Spikevax (53% of 138 the cohort), those aged \geq 70 years received a full dose, whereas those <70 years received a half-dose, as 139 per national guidelines. An additional six (7.4%) HCW and two (3.6%) older adults developed anti-N 140 antibodies during follow-up, reflecting breakthrough infections. Three of these infections, all in HCW, 141 occurred between December 2021-Jan 2022 and are likely Omicron. In longitudinal analyses that span 142 143 the entire study, participants with a post-vaccination SARS-CoV-2 infection are retained in their original "COVID-19 naive at study entry" groups but identified in the Figures, while in analyses that 144 focus on third dose responses, they are grouped in a single "prior COVID-19" group. 145

146

147 After two-dose vaccination, lower binding antibodies are associated with older age and burden of

148 chronic health conditions, but older adults mount strong responses after a third dose.

149	We measured total anti-RBD binding antibody concentrations in serum before and after
150	immunization (Figure 1A). As reported previously [12], antibody concentrations in older adults were
151	significantly lower than those in HCW one month after the first dose (a median of 2.00 [IQR 1.75-2.25]
152	log10 U/mL in HCW versus a median of 1.50 [IQR 1.05-1.99] in older adults), as well as one month
153	after the second dose (a median of 4.02 [IQR 3.88-4.25] in HCW versus a median of 3.74 [IQR 3.49-
154	3.91] in older adults) (Mann-Whitney; both p<0.0001). Three months following the second dose,
155	antibody concentrations had declined by $\sim 0.4 \log_{10}$ on average, to a median of 3.63 [IQR 3.44-3.83] in
156	HCW versus a median 3.32 [IQR 3.04-3.56] in older adults) (Mann-Whitney p<0.0001 for comparison
157	between groups). Six months following the second dose, antibody concentrations had declined by a
158	further ~0.3 log ₁₀ on average, to a median of 3.30 [IQR 3.09-3.47] in HCW versus a median 2.96 [IQR
159	2.68-3.20] in older adults (p<0.0001). This confirms that, following two-dose COVID-19 mRNA
160	vaccination, antibody concentrations remain consistently and significantly lower in older compared to
161	younger adults. By contrast, antibody concentrations in COVID-19 convalescent individuals remained
162	consistently higher than COVID-19 naive individuals at all time points after two doses. Six months
163	after the second dose for example, convalescent individuals maintained median responses of 3.50 (IQR
164	3.40-3.71) \log_{10} U/mL (p=0.027 compared to HCW; p<0.0001 compared to older adults).
165	Multivariable analyses of antibody concentrations after two doses, that adjusted for sex ,
166	ethnicity, number of chronic health conditions, first-dose vaccine brand, dosing interval and day of
167	specimen collection post-immunization confirmed that older age remained independently associated

with lower antibody concentrations at one and three months after the second dose (Table S1). One
month following the second dose for example, each decade of older age was associated with an ~0.06

170 log₁₀ lower antibody concentration (p=0.0067). A higher number of chronic conditions was also

171 independently associated with lower antibody concentrations at both these time points. Six months

172 following the second dose, a higher number of chronic health conditions remained the strongest independent correlate of lower responses, with each additional condition associated with an 0.14 log₁₀ 173 lower antibody concentration (p=0.0001). A longer dose interval was also associated with higher 174 175 antibody concentrations at all time points after the second dose (all p < 0.05), consistent with previous 176 reports [24-26]. COVID-19 convalescent status was also associated with maintaining 0.26 \log_{10} higher 177 antibody concentrations at three and six months following the second dose (both p < 0.05), consistent with superior durability of "hybrid" immunity induced by infection followed by vaccination [27-29]. 178 In both HCW and older adults, the third dose boosted antibody concentrations at least $\sim 0.3-0.4$ 179 180 log₁₀ higher than peak values observed after two doses (Wilcoxon paired test p<0.0001 for both groups). Binding antibodies in HCW rose to a median of 4.31 (IQR 4.13 to upper limit of quantification 181 [ULOQ]) whereas those in older adults rose to a median of 4.33 (4.14 to ULOQ) (p=0.33), indicating 182 that older and younger adults mounted comparable initial binding antibody responses following a third 183 dose. In multivariable analyses of third-dose responses, a higher number of chronic health conditions 184 was the sole significant correlate of lower antibody concentrations (p=0.0078), while having received 185 186 Spikevax as the third dose was associated with higher antibody concentrations (p=0.0091) (Table S2). 187 188 After two-dose vaccination, weaker virus neutralizing activity is associated with age and chronic 189 health conditions, but older adults mount strong responses after a third dose. We performed live SARS-CoV-2 neutralization assays to quantify the ability of plasma to block 190

191 virus infection of target cells (Figure 1B). Neutralizing activity is reported as the highest reciprocal 192 plasma dilution capable of preventing viral cytopathic effects in all wells of a triplicate assay, where a 193 reciprocal dilution of "10" indicates no or limited neutralization. As previously reported [12], one 194 vaccine dose largely failed to induce neutralizing activity in COVID-19 naïve individuals, though two

195	doses induced this activity in most participants, albeit at consistently lower levels in older compared to
196	younger adults. One month after the second dose for example, the median reciprocal dilution was 160
197	[IQR 80-160] in HCW versus 40 [IQR 20-80] in older adults (p<0.0001). Three months after the
198	second dose, neutralizing activity had declined by more than two-fold on average, to a median
199	reciprocal dilution of 40 (IQR 20-80) in HCW versus a median of 20 (IQR BLOQ-40) in older adults
200	(p<0.0001). Six months after the second dose, neutralizing activity had declined to below the limit of
201	quantification (BLOQ) in 58% of HCW and 83% of older adults (Mann-Whitney p=0.0048 for
202	comparison between groups). COVID-19 convalescent individuals by contrast maintained significantly
203	higher neutralizing activity compared to naive individuals at all time points following two-dose
204	vaccination. Multivariable analyses confirmed that older age remained significantly associated with
205	weaker neutralizing activity at one and three months after two-dose vaccination, while COVID-19
206	convalescent status was associated with superior neutralizing activity at all time points following two-
207	dose vaccination (all p≤0.0002) (Table S1).
208	A third vaccine dose boosted neutralizing activity in both HCW and older adults, achieving
209	responses that were two-fold and eight-fold higher than peak values after two doses, respectively
210	(Wilcoxon paired test p≤0.006 for both groups; Figure 1B). Specifically, the median reciprocal dilution
211	in HCW and older adults rose to 320 [IQR 160-320] and 320 [IQR 80-320], respectively (p=0.6),
212	indicating that older adults mounted comparable neutralizing responses to younger adults after three
213	doses. A multivariable analysis identified prior COVID-19 as the strongest independent predictor of
214	higher neutralizing activity after a third vaccine dose (p=0.0044; Table S2).
215	

216 After two-dose vaccination, binding antibody responses decline faster in those with a higher burden
217 of chronic conditions.

218	We next assessed temporal reductions in antibody concentrations after two-dose vaccination
219	(Figure 2A). Assuming exponential decay and restricting the analysis to participants with a complete
220	longitudinal data series with no values above the ULOQ, we estimated antibody concentration half-
221	lives to be a median of 59 [IQR 52-75] days in HCW versus a median of 52 [IQR 45-65] days in older
222	adults (p=0.016; Figure 2B). This suggests that, in addition to mounting overall weaker responses to
223	two-dose vaccination compared to younger adults, antibody concentrations in older adults also decline
224	more rapidly. In multivariable analyses however, a higher number of chronic health conditions
225	emerged as the sole independent correlate of antibody decline, with each additional condition
226	associated with a 5-day shorter half-life (p=0.017; Table 2). Furthermore, COVID-19 convalescent
227	status was associated with a 14-day longer antibody half-life after adjustment for other factors
228	(p=0.056), consistent with improved durability of hybrid immunity [27-29].

229

230 Humoral responses against Omicron following two and three vaccine doses

Given the rapid rise of the Omicron variant, we compared peak antibody responses against this 231 232 strain in plasma collected at one month after the second and third vaccine doses. Here, we grouped all 233 participants with prior COVID-19, regardless of infection timing, in the convalescent category. Overall, 234 IgG binding antibodies against the Omicron RBD, measured using the Meso Scale Diagnostics V-Plex 235 assay, were on average 0.4 to 0.5 log₁₀ U/mL lower than those against the wild type (WT; ancestral 236 Wuhan strain) RBD antigen after two and three doses (all within-group comparisons $p \le 0.0002$; Figure 237 **3A**). Nevertheless, the third dose universally boosted anti-Omicron IgG concentrations to an average of 238 $0.5 \log_{10}$ higher than levels induced by two doses (all within-group comparisons p<0.05). Consistent 239 with total binding antibody concentrations quantified using the Roche assay (Figure 1A), binding IgG 240 concentrations against the WT RBD were significantly higher in HCW compared to older adults after

241 two doses (p<0.0001) but reached equivalence after three doses (p=0.4). IgG concentrations capable of binding Omicron followed a similar pattern, with HCW showing marginally higher anti-Omicron IgG 242 levels compared to older adults after two doses (p=0.09), but equivalent levels after three doses 243 244 (p=0.49). A multivariable analysis of Omicron-specific IgG concentrations after three doses identified a 245 higher number of chronic health conditions as the strongest correlate of poorer responses, with each 246 additional condition associated with a $0.12 \log_{10}$ reduction in Omicron binding IgG (p=0.0033; Table 3). A longer interval between the first and second vaccine doses was marginally associated with a 247 lower third dose response (p=0.02). 248

249 We also assessed the ability of plasma to block the interaction between WT and Omicron RBD 250 and the cellular ACE2 receptor, which represents a higher throughput approach to estimate potential 251 virus neutralizing activity (also referred to as a surrogate virus neutralization test [30]). This activity 252 was significantly weaker against Omicron compared to WT RBD after both two and three doses in all groups (all within-group comparisons $p \le 0.0002$; Figure 3B), though the discrepancy was most 253 pronounced for older adults after two doses (where median activity against WT was 90% compared to 254 255 only 23% against Omicron). The third dose universally boosted anti-Omicron activity (all within-group 256 comparisons p<0.05), with, for example, median anti-Omicron activity in older adults rising from 23% 257 after two doses to 66% after three. Consistent with results for binding IgG antibodies, surrogate 258 neutralization of WT RBD was significantly higher in HCW compared to older adults after two doses 259 (p<0.0001), but reached equivalence after three doses (in fact, activities in older adults were slightly 260 higher at this time point; p=0.08). Surrogate neutralization of Omicron RBD followed a similar pattern, with HCW exhibiting significantly higher activity compared to older adults after two doses (p<0.0001), 261 262 but equivalent levels after three doses (p=0.2). In multivariable analyses, a higher number of chronic 263 health conditions was the strongest correlate of poorer surrogate neutralizing activity against Omicron

264	after three vaccine doses, with each additional condition associated with a $\sim 6\%$ reduction in this
265	activity (p=0.0046; Table 3). Male sex, a longer interval between the first and second doses, and the
266	number of days elapsed since the third dose also correlated with weaker responses after three doses (all
267	p<0.05).

268	Finally, we assessed plasma neutralizing activity against WT (ancestral USA-WA1/2020 strain)
269	and Omicron using a live virus assay in a subset of 20 HCW and 21 older adults who remained
270	COVID-19 negative throughout the study (Figure 4). Neutralizing activity against Omicron was
271	significantly weaker compared to WT following two and three doses in both groups (all p<0.0001). The
272	third dose nevertheless boosted anti-Omicron activity in both groups, where the increase in older adults
273	was particularly pronounced (from a median of BLOQ after the second dose to a median reciprocal
274	dilution of 40 after the third; p<0.0001). Consistent with binding IgG and surrogate neutralization
275	results, anti-Omicron neutralizing activity was significantly lower in older adults compared to HCW
276	after two vaccine doses (p=0.0003) but reached equivalence after the third dose (p=0.79).

278 DISCUSSION

At every time point following two doses of COVID-19 mRNA vaccine, antibody binding and 279 280 neutralizing activity were significantly weaker in older compared to younger adults. Antibody 281 concentrations were also less durable in older adults, though responses declined substantially in all 282 groups over time (e.g. by six months after the second dose, neutralizing activities had declined to 283 BLOQ in almost 60% of HCW and >80% of older adults). In multivariable analyses adjusting for sociodemographic, health and vaccine-related variables, a higher number of chronic health conditions 284 remained consistently and independently associated with weaker and less durable binding antibody 285 286 responses, while a longer interval between first and second doses was consistently associated with higher binding antibody responses after the second dose, as previously reported [24-26]. These findings 287 288 support public health decisions to provide third doses on or before the six-month mark, with older 289 adults receiving priority.

Third doses of COVID-19 vaccine increased antibody binding and neutralizing function to 290 levels that were significantly higher than those achieved by two doses, where the magnitude of 291 292 boosting in older adults was particularly prominent. Indeed, antibody binding, surrogate neutralization 293 and live virus neutralization activities in older adults were equivalent to those observed in younger 294 adults after three doses. Consistent with recent evidence [20, 21, 31-37], antibody responses against 295 Omicron were universally weaker than those against the ancestral strain after both two and three 296 vaccine doses; nevertheless, anti-Omicron responses in older adults reached equivalence to those 297 observed in younger adults after three doses. Notably, the number of chronic health conditions persisted as an independent correlate of weaker anti-Omicron responses, even after three doses. 298 299 Similar to other reports [27-29], our findings indicate that individuals who have contracted 300 COVID-19 are likely to benefit from vaccination. Compared to naïve participants, convalescent

301	individuals displayed a slower rate of antibody decline, and multivariable analyses demonstrated that
302	binding and neutralization activity was higher in this group at six months after the second dose .
303	Our study has several limitations. As the precise immune correlates of protection for SARS-
304	CoV-2 transmission and disease severity remain incompletely characterized [38], the implications of
305	our results on individual-level protection from SARS-CoV-2 infection and COVID-19 remain
306	uncertain. We did not investigate T-cell responses, which may play critical roles in protection against
307	severe COVID-19, particularly in the context of variants [39-46]. Our study was not powered to
308	investigate potential differences in immune responses between the two mRNA vaccines [47, 48], nor
309	differences in full vs. half-doses of Spikevax when administered as third doses to individuals ≥ 70
310	versus <70 years old, respectively, in Canada. Third dose responses were measured at a single time
311	point, so durability assessments are needed. Nevertheless, results provide additional insight into
312	COVID-19 mRNA vaccine immunogenicity in the elderly and in the context of an extended interval
313	between first and second doses (of up to 112 days).
314	In conclusion, while the observation of strong binding and neutralizing antibody responses to
315	third COVID-19 vaccine doses in older adults, including to Omicron, are encouraging, it will be
316	important to closely monitor the durability of these responses over time in this population.
317	

318 ACKNOWLEDGEMENTS

We thank the leadership and staff of Providence Health Care, including long-term care and assisted living residences, for their support of this study. We thank the phlebotomists and laboratory staff at St. Paul's Hospital, the BC Centre for Excellence in HIV/AIDS and Simon Fraser University for assistance. Above all, we thank the participants, without whom this study would not have been possible.

324

325 FUNDING

326 This work was supported by the Public Health Agency of Canada through a COVID-19 Immunology Task Force COVID-19 "Hot Spots" Award (2020-HQ-000120 to MGR, ZLB, MAB). 327 328 Additional funding was received from the Canadian Institutes for Health Research (GA2-177713 and 329 the Coronavirus Variants Rapid Response Network (FRN-175622) to MAB), the Canada Foundation for Innovation through Exceptional Opportunities Fund - COVID-19 awards (to MAB, MD, MN, RP, 330 ZLB) and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health 331 332 (R01AI134229 to RP). MLD and ZLB hold Scholar Awards from the Michael Smith Foundation for Health Research. LYL was supported by an SFU Undergraduate Research Award. GU and FHO hold 333 334 Ph.D. fellowships from the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative [grant # DEL-15-006]. The DELTAS Africa Initiative is an 335 336 independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating 337 Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's 338 Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome 339 Trust [grant # 107752/Z/15/Z] and the UK government. The views expressed in this publication are

those of the authors and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UKgovernment.

342

343 FIGURE LEGENDS

344 Figure 1. Longitudinal antibody binding and neutralization responses to spike RBD following

345 one, two and three COVID-19 vaccine doses. *Panel A*: Binding antibody responses to the SARS-

346 CoV-2 spike RBD in serum, in HCW (blue circles) and older adults (orange circles) who were COVID-

347 19 naive at study entry, as well as COVID-19 convalescent individuals (black circles) at six timepoints:

348 prior to vaccination (pre-vax), one month following the first dose, one, three and six months following

349 the second dose, and one month following the third vaccine dose. Individuals with post-vaccination

350 infections are indicated by red dots at their first N seropositive time point. Participant Ns are provided

at the bottom of the plot. A thick horizontal red bar represents the median; thinner horizontal red bars

352 represent the IQR. P-values were computed using the Mann-Whitney U-test (for comparisons between

353 groups) or the Wilcoxon matched pairs test (for comparisons across time points within a group) and are

354 uncorrected for multiple comparisons. ULOQ/LLOQ: upper/lower limit of quantification. *Panel B:*

355 same as A, but for virus neutralization activity, defined as the lowest reciprocal plasma dilution at

356 which neutralization was observed in all wells of a triplicate assay. Plasma samples showing

357 neutralization in fewer than three wells at a 1/20 dilution were coded as having a reciprocal dilution of

358 10, corresponding to the LLOQ in this assay. The highest dilution tested was 1/2560, which

359 corresponds to the ULOQ. Note that only a subset of pre-vaccine plasma samples was assayed for this360 activity.

362 Figure 2: Decay rates of serum binding antibody responses to spike RBD following two COVID-363 **19 vaccine doses.** Panel A: Temporal declines in serum binding antibody responses to spike RBD 364 following two vaccine doses in HCW (blue) and older adults (orange) who were COVID-19 naive at 365 study entry, as well as COVID-19 convalescent participants (black circles). ULOQ: upper limit of 366 quantification. Only participants with a complete longitudinal data series with no values above the 367 ULOQ are shown. *Panel B*: Binding antibody half-lives following two COVID-19 vaccine doses, 368 calculated by fitting an exponential curve to each participant's data shown in panel A. Participant Ns 369 are indicated at the bottom of the plot. Red bars and whiskers represent the median and IQR. P-values 370 were computed using the Mann-Whitney U-test and are uncorrected for multiple comparisons. 371 372 Figure 3: Anti-Omicron IgG binding and ACE2 displacement activities one month after the second and third COVID-19 vaccine doses. Panel A: Binding IgG responses in plasma to the wild-373 374 type (WT, ancestral Wuhan strain) and Omicron (OM) S-RBD, measured using the Meso Scale Diagnostics (MSD) V-Plex assay, in HCW (blue circles) and older adults (orange circles) who 375 376 remained COVID-19 naive throughout the study, as well as individuals with prior COVID-19 regardless of infection timing (COVID-19 convalescent; black circles) at one month after the second 377 378 and third COVID-19 vaccine doses. Participant Ns are shown at the bottom of the plot. A thick 379 horizontal red bar represents the median; thinner horizontal red bars represent the IQR. P-values were 380 computed using the Wilcoxon matched pairs test (for all within-group comparisons) or the Mann-381 Whitney U-test (for between-group comparisons) and are uncorrected for multiple comparisons. Panel B: same as A, but for ACE2 displacement activity, measured using the V-plex SARS-CoV-2 (ACE2) 382 assay, where results are reported in terms of % ACE2 displacement. 383

Figure 4: Anti-Omicron neutralization activities one month after the second and third COVID-19

- **vaccine doses.** Neutralization activities, reported as the lowest reciprocal plasma dilution at which
- 387 neutralization was observed in all wells of a triplicate assay, against the wild-type (WT, ancestral
- 388 WA1/2020 strain) and Omicron (OM) virus isolates a subset of HCW (blue circles) and older adults
- 389 (orange circles) who remained COVID-19 naive throughout the study. Participant Ns are shown at the
- bottom of the plot. A thick horizontal red bar represents the median; thinner horizontal red bars
- 391 represent the IQR. P-values were computed using the Wilcoxon matched pairs test (for within-group
- 392 comparisons) or the Mann-Whitney U-test (for between-group comparisons) and are uncorrected for
- 393 multiple comparisons.

394 REFERENCES

- 1. Fisman DN, Bogoch I, Lapointe-Shaw L, McCready J, Tuite AR. Risk Factors Associated With
- 396 Mortality Among Residents With Coronavirus Disease 2019 (COVID-19) in Long-term Care
- Facilities in Ontario, Canada. JAMA Netw Open **2020**; 3:e2015957.
- 2. Chinnadurai R, Ogedengbe O, Agarwal P, et al. Older age and frailty are the chief predictors of
- 399 mortality in COVID-19 patients admitted to an acute medical unit in a secondary care setting- a
- 400 cohort study. BMC Geriatr **2020**; 20:409.
- 401 3. Banerjee A, Pasea L, Harris S, et al. Estimating excess 1-year mortality associated with the COVID-
- 402 19 pandemic according to underlying conditions and age: a population-based cohort study.
 403 Lancet 2020; 395:1715-25.
- 404 4. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
 405 Vaccine. N Engl J Med 2021; 384:403-16.
- 406 5. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19
 407 Vaccine. N Engl J Med 2020; 383:2603-15.
- 408 6. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass
 409 Vaccination Setting. N Engl J Med 2021; 384:1412-23.
- 410 7. Grupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-CoV-2
 411 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J
- 412 Transplant **2021**; 21:2719-26.

413	8. Massarweh A, Eliakim-Raz N, Stemmer A, et al. Evaluation of Seropositivity Following BNT162b2
414	Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.
415	JAMA Oncol 2021 ; 7:1133-40.
416	9. Monin L, Laing AG, Munoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of
417	the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective
418	observational study. Lancet Oncol 2021; 22:765-78.
419	10. Collier DA, Ferreira I, Kotagiri P, et al. Age-related immune response heterogeneity to SARS-
420	CoV-2 vaccine BNT162b2. Nature 2021 ; 596:417-22.
421	11. Muller L, Andree M, Moskorz W, et al. Age-dependent Immune Response to the Biontech/Pfizer
422	BNT162b2 Coronavirus Disease 2019 Vaccination. Clin Infect Dis 2021; 73:2065-72.
423	12. Brockman MA, Mwimanzi F, Lapointe HR, et al. Reduced magnitude and durability of humoral
424	immune responses to COVID-19 mRNA vaccines among older adults. J Infect Dis 2021; Online
425	ahead of print. Accepted 9 Dec 2021. doi: 10.1093/infdis/jiab592.
426	13. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-
427	19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 2021;
428	398:2093-100.
429	14. Gilboa M, Mandelboim M, Indenbaum V, et al. Early Immunogenicity and safety of the third dose
430	of BNT162b2 mRNA Covid-19 vaccine among adults older than 60 years; real world experience.
431	J Infect Dis 2021; Online ahead of print. Accepted, 29 Nov 2021. doi: 10.1093/infdis/jiab584.

- 432 15. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 Vaccine Booster against
- 433 Covid-19 in Israel. N Engl J Med **2021**; 385:1393-400.
- 434 16. Falsey AR, Frenck RW, Jr., Walsh EE, et al. SARS-CoV-2 Neutralization with BNT162b2 Vaccine
- 435 Dose 3. N Engl J Med **2021**; 385:1627-9.
- 436 17. Mizrahi B, Lotan R, Kalkstein N, et al. Correlation of SARS-CoV-2-breakthrough infections to
- 437 time-from-vaccine. Nat Commun **2021**; 12:6379.
- 438 18. Goldberg Y, Mandel M, Bar-On YM, et al. Waning Immunity after the BNT162b2 Vaccine in

439 Israel. N Engl J Med **2021**; 385:e85.

- 440 19. Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19
 441 Vaccine over 6 Months. N Engl J Med 2021; 385:e84.
- 20. Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 Vaccine
- 443 against Omicron Variant in South Africa. N Engl J Med **2022**; 386:494-6.
- 444 21. Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer
- BNT162b2 neutralization. Nature 2021; Online ahead of print. Accepted, 23 Dec 2021. doi:
 10.1038/s41586-021-04387-1.
- 22. Song JS, Lee J, Kim M, et al. Serial Intervals and Household Transmission of SARS-CoV-2
 Omicron Variant, South Korea, 2021. Emerg Infect Dis 2022; 28.
- 449 23. Bentley E, Mee ET, Routley S, et al. Collaborative Study for the Establishment of a WHO
- 450 International Standard for SARS-CoV-2 RNA. World Health Organization, Expert Committee on
- 451 Biological Standardization **2020**:WHO/BS/2020.402.

452	24. Amirthalingam G, Bernal JL, Andrews NJ, et al. Serological responses and vaccine effectiveness
453	for extended COVID-19 vaccine schedules in England. Nat Commun 2021; 12:7217.
454	25. Parry H, Bruton R, Stephens C, et al. Differential immunogenicity of BNT162b2 or ChAdOx1
455	vaccines after extended-interval homologous dual vaccination in older people. Immun Ageing
456	2021 ; 18:34.
457	26. Payne RP, Longet S, Austin JA, et al. Immunogenicity of standard and extended dosing intervals of
458	BNT162b2 mRNA vaccine. Cell 2021; 184:5699-714 e11.
459	27. Cho A, Muecksch F, Schaefer-Babajew D, et al. Anti-SARS-CoV-2 receptor-binding domain
460	antibody evolution after mRNA vaccination. Nature 2021; 600:517-22.
461	28. Stamatatos L, Czartoski J, Wan YH, et al. mRNA vaccination boosts cross-variant neutralizing
462	antibodies elicited by SARS-CoV-2 infection. Science 2021; 372:1413-8.
463	29. Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth against
464	SARS-CoV-2 one year after infection. Nature 2021; 595:426-31.
465	30. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on
466	antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol 2020;
467	38:1073-8.
468	31. Doria-Rose NA, Shen X, Schmidt SD, et al. Booster of mRNA-1273 Strengthens SARS-CoV-2
469	Omicron Neutralization. medRxiv 2021; Posted 20 Dec 2021. doi:
470	10.1101/2021.12.15.21267805. Preprint.

471	32. Schmidt F, Muecksch F, Weisblum Y, et al. Plasma neutralization properties of the SARS-CoV-2
472	Omicron variant. medRxiv 2021; Posted 13 Dec 2021. doi: 10.1101/2021.12.12.21267646.
473	Preprint.
474	33. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters
475	induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 2022; 185:457-66 e4.
476	34. Muik A, Lui BG, Wallisch AK, et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2
477	mRNA vaccine-elicited human sera. Science 2022; 375:678-80.
478	35. Debes AK, Xiao S, Egbert ER, et al. Comparison of total and neutralizing SARS-CoV-2 spike
479	antibodies against omicron and other variants in paired samples after two or three doses of
480	mRNA vaccine. medRxiv 2022; Posted 31 Jan 2022. doi: 10.1101/2022.01.26.22269819.
481	Preprint.
482	36. Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other
483	SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect
484	2022 ; 11:337-43.
485	37. Muecksch F, Wang Z, Cho A, et al. Increased Potency and Breadth of SARS-CoV-2 Neutralizing
486	Antibodies After a Third mRNA Vaccine Dose. bioRxiv 2022; Posted 15 Jan 2022. doi:
487	10.1101/2022.02.14.480394. Preprint.:2022.02.14.480394.
488	38. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic
489	SARS-CoV-2 infection. Nat Med 2021; 27:2032-40.

490	39. Redd AD, Nardin A, Kared H, et al. Minimal cross-over between mutations associated with
491	Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19
492	convalescent individuals. bioRxiv 2021; Posted 9 Dec 2021. doi: 10.1101/2021.12.06.471446.
493	Preprint.
494	40. Peng Y, Felce SL, Dong D, et al. An immunodominant NP105-113-B*07:02 cytotoxic T cell
495	response controls viral replication and is associated with less severe COVID-19 disease. Nat
496	Immunol 2022 ; 23:50-61.
497	41. Swadling L, Diniz MO, Schmidt NM, et al. Pre-existing polymerase-specific T cells expand in
498	abortive seronegative SARS-CoV-2. Nature 2022; 601:110-7.
499 500	42. Grifoni A, Sidney J, Vita R, et al. SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19. Cell Host Microbe 2021 ; 29:1076-92.
501	43. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8
502	months after infection. Science 2021; 371:eabf4063.
503	44. Riou C, Keeton R, Moyo-Gwete T, et al. Escape from recognition of SARS-CoV-2 variant spike
504	epitopes but overall preservation of T cell immunity. Sci Transl Med 2022; 14:eabj6824.
505	45. Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS-CoV-2 spike cross-recognize
506	Omicron. Nature 2022; Online ahead of print. Accepted, 31 Jan 2022. doi: 10.1038/s41586-022-
507	04460-3.

508	46. Liu J, Chandrashekar A, Sellers D, et al. Vaccines Elicit Highly Conserved Cellular Immunity to
509	SARS-CoV-2 Omicron. Nature; Online ahead of print, 31 Jan 2022. doi: 10.1038/s41586-022-
510	04465-у.
511	47. Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 Antibody
512	Response Following Vaccination With BNT162b2 and mRNA-1273. JAMA 2021; 326:1533-5.
513	48. Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines
514	in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During
515	Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare
516	Safety Network, March 1-August 1, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1163-6.

Table 1: Participant characteristics and sampling information

Variable category	Characteristic	Healthcare Workers (n=81)	Older Adults (n=56)	COVID-19 Convalescent at study entry (n=14)
Sociodemographic/health	Age in years, median [IQR] ^a	41 [35-51]	78 [73-83]	48 [36-87]
	Female sex, n (%)	61 (75%)	38 (68%)	10 (71%)
	White/Caucasian ethnicity, n (%)	37 (46%)	43 (77%)	7 (50%)
	Chronic health or immunosuppressive conditions, median [IQR]	0 [0-0]	1 [0-2]	0 [0-1]
Vaccine information	Comirnaty, First mRNA Vaccine, n (%)	80 (99%)	48 (86%)	13 (93%)
	Comirnaty, Second mRNA Vaccine, n (%)	79 (98%)	46 (82%)	13 (93%)
	Time between first and second doses in days, median [IQR]	97 [91-102]	76 [45-85]	112 [87-118]
	Comirnaty, Third mRNA Vaccine, n (%) ^b	32/61 (52%)	19/47 (40%)	3/6 (50%)
	Time between second and third dose in days, median [IQR]	210 [200-241]	169 [160-231]	189 [170-194]
Specimen collection	Specimens collected pre-vaccine, n (%)	80 (99%)	49 (88%)	13 (93%)
*	Specimens collected one month after first dose, n (%)	79 (98%)	49 (88%)	13 (93%)
	Day of specimen collection one month after first dose, median [IQR] days	28 [27-30]	30 [28-32]	31 [28-32]
	Specimens collected one month after second dose, n (%)	81 (100%)	55 (98%)	14 (100%)
	Day of specimen collection one month after second dose, median [IQR] days	29 [29-32]	29 [29-31]	32 [30-36]
	Specimens collected three months after second dose, n (%)	79 (98%)	53 (95%)	13 (93%)
	Day of specimen collection three months after second dose, median [IQR] days	90 [90-91]	90 [89-92]	90 [87-91]
	Specimens collected six months after second dose, n (%)	78 (96%)	40 (71%)	10 (71%)
	Day of specimen collection six months after second dose, median [IQR] days	181 [179-182]	176 [167-182]	180 [179-181]
	Specimens collected one month after third dose, n (%)	61 (75%)	47 (84%)	6 (38%)
	Day of specimen collection one month after third dose, median [IQR] days	30 [29-31]	32 [29-33]	30 [29-30]
COVID-19 post-vax	Anti-N seroconversion during study follow-up	6 (7.4%)	2 (3.6%)	-

^a interquartile range
^b denominators are the n of specimens collected one month after third dose

Table 2: Multivariable analysis of the relationship between sociodemographic, health and vaccine-related variables on serum

Outcome measure	Variable	Estimate	95% CI	p-value
Ab half-life after two vaccine doses	Age (per year)	0.058	-0.17 to 0.29	0.61
	Male sex	5.31	-2.57 to 13.18	0.18
	White ethnicity	3.11	-4.67 to 10.88	0.43
	# chronic conditions (per add'l)	-4.62	-8.39 to -0.85	0.017
	Spikevax as first dose	3.37	-13.26 to 20.00	0.69
	Dose interval (per day)	0.00014	-0.16 to 0.16	0.99
	COVID-19 convalescent ^a	13.78	-0.37 to 27.93	0.056

antibody half-life following two-dose COVID-19 mRNA vaccination


^a participants with positive anti-N serology at study entry


Table 3: Multivariable analyses of the relationship between sociodemographic, health and vaccine-related variables on Omicron-

• • • • • •	• • • • • •	• 11 •		
specific humoral	immunogenicity	measures following	three-dose (()	VID-19 mRNA vaccination
specific numbra	minunogementy	measures renowing		

Humoral measure	Variable	1 mo after 3rd dose				
numoral measure	variable	Estimate	95% CI	p-value		
anti-Omicron RBD IgG (log10) ^a	Age (per year)	0.0035	-0.0027 to 0.0097	0.26		
	Male sex	-0.14	-0.34 to 0.054	0.15		
	White ethnicity	-0.018	-0.21 to 0.17	0.85		
	# chronic conditions (per add'l)	-0.12	-0.20 to -0.041	0.0033		
	Spikevax as third dose (vs. Comirnaty)	0.15	-0.039 to 0.34	0.12		
	Interval between 1st and 2nd dose (per day)	-0.0066	-0.012 to -0.0011	0.020		
	Interval between 2nd and 3rd dose (per day)	0.00043	-0.0034 to 0.0042	0.83		
	Days since 3rd vaccine dose	-0.0086	-0.038 to 0.021	0.56		
	Prior COVID-19 ^b	0.1	-0.16 to 0.37	0.43		
anti-Omicron ACE2 % displacement ^a	Age (per year)	0.29	-0.046 to 0.63	0.090		
	Male sex	-12.38	-23.16 to -1.60	0.025		
	White Ethnicity	-2.36	-12.74 to 8.01	0.65		
	# chronic conditions (per add'l)	-6.41	-10.80 to -2.03	0.0046		
	Spikevax as third dose (vs. Comirnaty)	1.69	-8.58 to 11.97	0.74		
	Interval between 1st and 2nd dose (per day)	-0.41	-0.71 to -0.11	0.0079		
	Interval between 2nd and 3rd dose (per day)	-0.038	-0.25 to 0.17	0.72		
	Days since 3rd vaccine dose	-1.82	-3.43 to -0.21	0.027		
	Prior COVID-19 ^b	12.28	-2.11 to 26.67	0.094		


^a Measured using the Meso Scale Diagnostics (MSD) V-plex assay system
 ^b Includes all participants with positive anti-N serology at any time during the study (*i.e.* both pre- and post-vaccine COVID-19 cases)







b

Figure 2





b



Humoral	Variable	1 mo after 2nd dose		3 mo after 2nd dose			6 mo after 2nd dose			
measure		Estimate	95% CI	p-value	Estimate	95% CI	p-value	Estimate	95% CI	p-value
anti-RBD	Age (per year)	-0.0061	-0.010 to -0.0017	0.0067	-0.0047	-0.0085 to -0.00077	0.019	-0.0029	-0.0076 to 0.0018	0.22
Abs	Male sex	0.012	-0.14 to 0.17	0.88	0.089	-0.052 to 0.23	0.21	0.062	-0.083 to 0.21	0.40
$(\log_{10})^a$	White ethnicity	0.098	-0.056 to 0.25	0.21	0.15	0.012 to 0.29	0.033	0.089	-0.055 to 0.23	0.22
	# chronic cond. (per add'l)	-0.096	-0.17 to -0.022	0.011	-0.11	-0.18 to -0.047	0.001	-0.14	-0.21 to -0.068	0.0001
	Spikevax as first dose	0.25	-0.038 to 0.54	0.088	0.32	0.054 to 0.59	0.019	0.26	-0.039 to 0.57	0.087
	Dose interval (per day)	0.0034	0.00011 to 0.0067	0.043	0.0054	0.0025 to 0.0083	0.0003	0.0049	0.00194 to 0.0079	0.0014
	Days since 2nd dose	0.0039	-0.026 to 0.033	0.80	0.015	-0.0098 to 0.040	0.24	0.00095	-0.0088 to 0.010	0.85
	COVID-19 convalescent ^c	0.16	-0.087 to 0.42	0.20	0.23	0.0081 to 0.46	0.042	0.26	0.00938 to 0.51	0.042
Viral	Age (per year)	-0.018	-0.033 to -0.0030	0.019	-0.020	-0.034 to -0.0052	0.008	-0.0022	-0.016 to 0.012	0.75
neut	Male sex	-0.33	-0.85 to 0.18	0.21	0.22	-0.30 to 0.75	0.40	0.14	-0.29 to 0.57	0.53
$(log_2)^b$	White ethnicity	-0.075	-0.59 to 0.43	0.77	0.27	-0.24 to 0.78	0.30	0.067	-0.36 to 0.49	0.76
	# chronic cond. (per add'l)	-0.10	-0.34 to 0.14	0.42	-0.16	-0.40 to 0.095	0.22	-0.0080	-0.21 to 0.20	0.94
	Spikevax as first dose	0.86	-0.098 to 1.82	0.078	0.71	-0.30 to 1.7	0.17	0.81	-0.088 to 1.71	0.077
	Dose interval (per day)	0.0066	-0.0044 to 0.018	0.24	-0.00046	-0.011 to 0.010	0.93	0.0074	-0.0015 to 0.016	0.10
	Days since 2nd dose	0.0040	-0.094 to 0.10	0.94	-0.066	-0.16 to 0.026	0.16	0.010	-0.019 to 0.039	0.48
	COVID-19 convalescent	1.64	0.81 to 2.47	0.0001	1.84	1.0 to 2.7	<0.0001	1.46	0.72 to 2.19	0.0002

Table S1: Multivariable analyses of the relationship between sociodemographic, health and vaccine-related variables on immunogenicity measures following two-dose COVID-19 mRNA vaccination

measured using the Elecsys Anti-SARS-CoV-2 S assay

for viral neutralization, reciprocal plasma dilutions were log₂ transformed prior to multivariable analysis.

participants with positive anti-N serology at study entry

Humoral measure	Variable		1 mo after 3rd dose			
Humoral measure	variable	Estimate	95% CI	p-value		
anti-RBD Abs $(log_{10})^a$	Age (per year)	0.0018	-0.0011 to 0.0048	0.22		
	Male sex	0.0080	-0.086 to 0.10	0.87		
	White ethnicity	0.0089	-0.082 to 0.10	0.85		
	# chronic conditions (per add'l)	-0.053	-0.091 to -0.014	0.0078		
	Spikevax as third dose (vs. Comirnaty)	0.12	0.030 to 0.21	0.0091		
	Interval between 1st and 2nd dose (per day)	-0.00064	-0.0033 to 0.0020	0.63		
	Interval between 2nd and 3rd dose (per day)	0.00037	-0.0014 to 0.0022	0.69		
	Days since 3rd vaccine dose	0.0016	-0.013 to 0.016	0.82		
	Prior COVID-19 ^c	0.070	-0.057 to 0.20	0.28		
Viral neut. (log ₂) ^b	Age (per year)	0.022	0.0025 to 0.042	0.028		
	Male sex	-0.075	-0.70 to 0.55	0.81		
	White ethnicity	-0.28	-0.88 to 0.33	0.37		
	# chronic conditions (per add'l)	-0.17	-0.43 to 0.081	0.18		
	Spikevax as third dose (vs. Comirnaty)	0.70	0.11 to 1.29	0.021		
	Interval between 1st and 2nd dose (per day)	0.012	-0.0056 to 0.029	0.18		
	Interval between 2nd and 3rd dose (per day)	0.013	0.00097 to 0.025	0.035		
	Days since 3rd vaccine dose	-0.028	-0.12 to 0.065	0.55		
	Prior COVID-19 ^c	1.23	0.39 to 2.06	0.0044		

Table S2: Multivariable analyses of the relationship between sociodemographic, health and vaccine-related variables on humoral responses following three-dose COVID-19 mRNA vaccination

^a Measured using the Elecsys Anti-SARS-CoV-2 S assay

^b Viral neutralization results were log₂-transformed prior to multivariable analysis ^c Includes all participants with positive anti-N serology at any time during the study (*i.e.* both pre- and post-vaccine COVID-19 cases)